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Metabolic acidosis: An unrecognized cause of morbidity in the
patient with chronic kidney disease. In patients with chronic kid-
ney disease, metabolic acidosis can occur as a result of insuffi-
cient ammoniagenesis within the damaged kidney. This, in turn,
can bring about a variety of sequella that have their basis in hor-
monal and cellular abnormalities that effect stunted growth, loss
of muscle and bone mass, and negative nitrogen balance. Cel-
lular mechanisms accounting for these findings are reviewed.
In bone, metabolic acidosis causes direct dissolution of bone;
ostoeclastic activity is increased while osteoblastic activity is
suppressed. In muscle, branched-chain amino acid oxidation is
increased and the ubiquitin-proteasome pathway is activated:
muscle wasting results. Even a modest degree of metabolic aci-
dosis can be harmful and can initiate a series of maladaptive
responses that are not easily reversed, although there is evi-
dence that alkali therapy can be beneficial in reversing these
responses.
By definition, metabolic acidosis is characterized as an
abnormal state of reduced alkalinity in the blood and
body tissues and can occur in a variety of medical condi-
tions. In chronic kidney disease, metabolic acidosis occurs
as a result of a lack of sufficient ammoniagenesis within
the damaged kidney and manifests itself in a number of
nonspecific clinical conditions including nausea, vomit-
ing, fatigue, anorexia, and exercise intolerance. These
clinical manifestations have a pathological basis result-
ing from changes in hormonal levels and alterations in
basic cellular mechanisms of growth and synthesis.
ALTERATIONS IN GROWTH AND BONE
METABOLISM WITH METABOLIC ACIDOSIS
One of the earliest observations indicating that growth
impairment could be related to metabolic acidosis
stemmed from studies of infants and children with re-
nal tubular acidosis. In this group, growth is uniformly
stunted and growth impairment is discernable as early
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as 6 months of age. Although there may be other ge-
netic abnormalities in this population, the patients have
in common a low level of serum bicarbonate. Noting this
commonality, McSherry and Morris [1] postulated that
correction of the acidosis would result in improvement
of growth. Initially, their hypothesis was difficult to prove
as they underestimated the amounts of alkali that would
be required to fully correct the acidosis; however, they
ultimately were able to demonstrate that not only could
impairment in growth be prevented, but it also could be
corrected if sufficient amounts of alkali were provided in
the diet. Increasing alkali in the diet has become a main-
stay in treatment for patients with renal tubular acidosis.
More recently, Kaiser [2] suggested that optimal growth
in pediatric dialysis patients hinged on maintenance of
normal bicarbonate levels. He studied pediatric patients
on continuous ambulatory peritoneal dialysis (CAPD),
intermittent peritoneal dialysis (IPD), and hemodialysis
(HD) and noted slight but statistical differences in serum
bicarbonate levels among the various dialysis modalities
ranging from 2l ± 2 mMolar in HD patients to 24 ± 2
mMolar in the CAPD group. Only in the CAPD group
were patients able to achieve normal growth rates. Al-
though the study did not control for differences in dial-
ysis delivery, ie, dialysis adequacy as measured by KT/V,
the results underscored the importance that continuous
control of acidosis appeared to have on growth in this
population.
Some insight into how metabolic acidosis stunts growth
has been gained through studies by Brungger and
colleagues [3] of healthy volunteers who developed
chronic metabolic acidosis through the administration
of ammonium chloride. Although the insulin-like growth
factor (IGF)-1 response to growth hormone was signifi-
cantly blunted during metabolic acidosis and resulted in
significantly decreased serum IGF-1 concentrations, the
growth hormone response to growth hormone releasing
factor was markedly enhanced. These results suggest that
the primary defect in the growth hormone/IGF-1 axis is
caused by an impaired response to circulating growth hor-
mone and diminution of normal negative feedback inhi-
bition of IGF-1 on growth hormone.
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Beyond its negative effects on growth hormone,
metabolic acidosis alters calcium metabolism. Under nor-
mal conditions, an acid load is excreted by the kidney in
the form of ammonium or titratable acid. With aging or
with chronic kidney disease, nephron loss compromises
ammoniagenesis, and acid production exceeds acid losses.
As a consequence of subnormal rates of acid excretion,
cellular mechanisms of adaptation are activated, which
bring acid base balance toward normal. In particular,
serum bicarbonate concentration stabilizes as excess hy-
drogen ions are neutralized by the continuous release of
alkali from bone [4]. Such responses occur not only in pa-
tients with chronic kidney disease but also in the aged as
well [5]. Buffering of bone carbonate by hydrogen ions re-
sults in bone demineralization with liberation of sodium,
potassium, and calcium. Ultimately, the excess calcium is
lost in the urine. Besides the direct physiochemical disso-
lution of bone, metabolic acidosis stimulates osteoclasts
and inhibits osteoblasts [6], further worsening negative
bone turnover.
The importance of bone as a source of alkali has been
illustrated in a number of studies.
Sebastian and colleagues [7] studied calcium and phos-
phorus balance in 18 postmenopausal women treated
with potassium bicarbonate. The authors hypothesized
that a low level of metabolic acidosis typically derives
from dietary protein intake. In normal subjects, this
mechanism would result in positive acid balance and,
over a lifetime, the counteraction of endogenous acid
by base mobilized from the skeleton could contribute
to a decrease in bone mass. Carefully executed balance
studies demonstrated that the use of potassium bicarbon-
ate improved calcium and phosphorus balance, reduced
bone resorption, and increased the rate of bone forma-
tion when subjects were on a usual dietary protein intake.
In the absence of potassium bicarbonate, calcium and
phosphorus balance was negative, bone resorption was
increased, and bone formation decreased. These findings
further illustrate that not only kidney disease patients,
but all individuals, have to be concerned about metabolic
acidosis. Moreover, the importance of regulating dietary
protein intake on controlling metabolic acidosis was illus-
trated in a series of metabolic studies done by Lutz [8].
Volunteer subjects ranging in age from 38 to 62 years
were placed on either a low protein diet of 44 g/day
(0.6 g/kg/ideal body weight), a high protein diet of 102
g/day (1.4 g/kg/ideal body weight), or a high protein diet
of 102 g/day (1.4 g/kg/ideal body weight) supplemented
with alkali in the form of potassium bicarbonate. Calcium,
phosphorus, and magnesium intakes were also held con-
stant. Subjects on the low protein diet or the high protein
diet supplemented with alkali maintained positive cal-
cium balance. Intake of a high protein diet with no potas-
sium bicarbonate supplementation resulted in negative
calcium balance with a significant increase in urinary cal-
cium losses, suggesting that excess acid generated by the
diet was buffered by endogenous alkali from bone. No
significant differences in arterialized blood pH or serum
bicarbonate concentrations were noted among any of the
groups.
Besides its direct effect on bone metabolism, metabolic
acidosis can alter parathyroid hormone’s sensitivity to
ionized calcium. Graham and colleagues [9] studied
8 hemodialysis patients with secondary hyperparathy-
roidism. They found that correction of metabolic acidosis
increased the sensitivity of the parathyroid gland to ion-
ized calcium, resulting in its suppression. Calcitriol did
not have the same effect; however, rapid correction of
metabolic acidosis in patients with renal failure resulted
in a 2-fold response: circulating intact parathyroid hor-
mone levels were suppressed, and vitamin D3 levels in-
creased significantly [10].
OTHER HORMONAL ABNORMALITIES WITH
METABOLIC ACIDOSIS
Insulin resistance has been reported in patients with
moderate to severe uremia. Fasting glucose levels tend
to be elevated despite higher circulating levels of in-
sulin, and there is an abnormal response to a glucose
load. As a result, these patients have reduced sensi-
tivity to the hypoglycemic action of insulin; defects in
insulin secretion have also been reported [11]. As a com-
plication of uremia, metabolic acidosis has been reported
to contribute to insulin resistance. In rat studies, correc-
tion of metabolic acidosis partially corrects insulin re-
sistance [12]. In patients not yet on dialysis, correction
of metabolic acidosis with sodium bicarbonate has been
shown to increase insulin sensitivity [13]. Mak [14] stud-
ied 8 patients on chronic hemodialysis before and after
2 weeks of oral sodium bicarbonate therapy to correct
the metabolic acidosis, and measured insulin sensitivity
using the hyperinsulinemic euglycemic clamp technique.
He also measured insulin secretion by the hyperglycemic
clamp technique. Seven healthy volunteers served as con-
trol subjects. To control for the effect of the additional
sodium, the patients and controls were also studied after
2 weeks of sodium chloride. Mak found that sodium bi-
carbonate therapy led to significant increases in venous
pH and serum bicarbonate levels. There was no significant
change in parathyroid hormone concentrations; however,
circulating 1,25 dihydroxyvitamin D3 levels, which had
been low prior to treatment with sodium bicarbonate,
increased significantly following treatment. Insulin sen-
sitivity and secretion increased as well following sodium
bicarbonate therapy. Sodium chloride had no effect.
Still other hormones are affected by metabolic acido-
sis. In normal adults, metabolic acidosis lowers serum
levels of free triiodothyronine (T3) and thyroxine (T4),
and thyroid-stimulating hormone (TSH) levels are mildly
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increased. The concentration of reverse T3 is unchanged.
The clinical significance of this mild hypothyroid state is
unknown, but it could affect both calcium and protein
metabolism.
PROTEIN METABOLISM
Because dietary protein intake is a major source of
acid that must be neutralized by the kidney, any impair-
ment in the organ’s ability to neutralize this excess acid
would force the body to rely on alternative sources of al-
kali. When these alternative sources, such as bone, fail to
neutralize the excess acid, other maladaptive responses
occur. In particular, protein degradation increases. Un-
til recently, cellular mechanisms accounting for this mal-
adaptive response have been largely obscure, but the case
for metabolic acidosis is compelling.
Under normal conditions, the dietary intake of protein
ranges from 1.0 to 1.5 gm/kg ideal body weight. These di-
etary proteins are catabolized to amino acids, which can
be used in the synthesis of new proteins, oxidized as an
energy source, or stored in the body’s amino acid pool.
Although the normal dietary intake of 70 to 110 grams of
protein per day appears to be large, it is dwarfed by the
enormous amounts of protein synthesized and degraded
by the body each day. Studies suggest that the normal
adult will synthesize and degrade about 4 kg of protein
per day [15]. Under conditions of dietary protein restric-
tion, the body adapts by decreasing essential amino acid
oxidation. More severe dietary protein restriction results
in minimal rates of amino acid oxidation, and protein
degradation decreases [16]. This adaptive process is in-
sufficient to maintain neutral nitrogen balance. Never-
theless, body protein losses are minimized to prevent sig-
nificant decreases in muscle mass. If protein degradation
is stimulated in this setting by chronic kidney disease or
metabolic acidosis, protein losses could be considerable.
It has long been noted that patients with chronic kid-
ney disease appear malnourished. In the early 17th cen-
tury, physicians from France and England who visited
St. Petersburg to attend Peter the Great noted how ema-
ciated he appeared. They concluded that his appearance
was due largely to the sequella of his disease. About 300
years later, Lyon, Dunlop, and Stewart [17] advocated the
use of alkali for the treatment of patients with kidney dis-
ease. They noted a connection between renal failure and
metabolic acidosis, and attributed the latter as a cause
of malnutrition in this disease. As did others, they noted
that a low protein diet was beneficial for treatment of
patients with kidney disease. Giordano [18] would later
verify through detailed dietary records that there was a
relationship between a reduction in protein intake and
relief of uremic symptoms. Today we know that protein,
particularly animal protein, is rich in sulfur-containing
amino acids and is a major source of acid in the diet. It is
this acidosis that has a negative impact on the body’s pro-
tein stores. Coles [19], who performed careful measure-
ments of various muscle groups in patients with chronic
kidney disease, demonstrated that a decrease in muscle
mass was often masked by fluid retention. He concluded
that patients with kidney disease were malnourished. De-
spite dialytic intervention, malnutrition remains a com-
mon malady among dialysis patients and is a negative pre-
dictor of dialysis outcome. Lowrie and Lew [20] studied
12,000 dialysis patients and found that low serum albu-
min was highly correlated with an increased risk of death.
They found that hemodialysis patients with a serum albu-
min level <2.5 had a 10-fold increased risk of dying within
the 3-month period following the study measurement.
CELLULAR MECHANISMS RESULTING IN
PROTEIN DEGRADATION
How does metabolic acidosis cause protein wasting?
It would seem intuitively obvious that metabolic acido-
sis would act directly on cells and lower intracellular
pH, but the available evidence suggests that this is not
the case. When metabolic acidosis is induced in rats by
feeding them ammonium chloride in the diet or by in-
fusing them with hydrochloric acid, or by induction of
chronic renal failure, intracellular pH as measured by
31 P NMR (phosphorus nuclear magnetic resonance) is
maintained despite the severity of the low extracellular
pH [21]. This work suggests that other signal transduc-
tion pathways must be involved when metabolic acido-
sis stimulates muscle proteolysis. A prime mediator of
this process appears to be glucocorticoids. When May
and colleagues [22] induced chronic renal failure in rats,
they noted that urinary corticosterone levels increased
in proportion to the degree of metabolic acidosis. More-
over, they found that only the acidotic rats had acceler-
ated rates of muscle protein degradation. When sufficient
sodium bicarbonate was added to the diet to correct the
acidosis, urinary corticosterone levels remained elevated
but rates of protein degradation were no different from
those in control rats. The authors concluded that both
acidosis and a high glucocorticoid level were required to
stimulate muscle proteolysis. Garibatto and colleagues
[23] extended these results to patients with chronic kidney
disease. They also found an inverse correlation between
serum cortisol and bicarbonate levels—ie, the lower the
serum bicarbonate levels, the higher the serum cortisol
levels. They also measured rates of protein degradation
in these patients and found that higher rates of protein
degradation correlated directly with serum cortisol levels
and indirectly with serum bicarbonate levels. Although a
correlation between serum cortisol levels and serum bi-
carbonate levels exists in the setting of metabolic acidosis,
it does not prove causality. More definitive evidence for
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this cause-and-effect relationship comes from both cell
culture work and animal studies.
Isozaki and colleagues [24] acidified BC3H-1 myocytes
in the presence and absence of RU486, a potent steroid
receptor antagonist. Acidification of the media contain-
ing these muscle cells stimulated protein degradation,
but protein degradation was inhibited when RU486 was
added to the media despite the presence of acidification.
Glucocorticoids alone did not stimulate protein degra-
dation. Only in the presence of both glucocorticoids and
acidosis could protein degradation occur. May and col-
leagues extended these findings in vivo [25]. They studied
adrenalectomized rats in which metabolic acidosis was in-
duced in the presence or absence of physiological doses of
glucocorticoids. They found that metabolic acidosis alone
or glucocorticoids alone in these adrenalectomized rats
had no effect on rates of protein degradation compared
with control animals. Only in the presence of both glu-
cocorticoids and acidosis did accelerated rates of protein
degradation occur.
Beyond the requirement for glucocorticoids, cellular
pathways that are stimulated by acidosis have been un-
covered. It is known that there are at least 4 cellular
pathways by which proteins can be degraded. These in-
clude a lysosomal pathway, a calcium activated path-
way requiring thiol proteases, an adenosine triphos-
phate (ATP)-dependent proteasome pathway involving
ubiquitin and the proteasome, and an ATP-independent
pathway. Available evidence suggests that it is the
ATP-dependent ubiquitin proteasome pathway that
plays the predominant role by which muscle is degraded
under conditions of metabolic acidosis. In this pathway
[26], proteins designated for degradation are bound to
ubiquitin and then targeted for digestion by a cytoso-
lic protein complex called the proteasome. The ubiquitin
covalently binds to lysine residues in a process requir-
ing ATP. This binding by a series of ubiquitin proteins
marks the proteins for subsequent proteolysis. Subse-
quently, these ubiquinated proteins are transported to the
large doughnut-shaped proteasome and then degraded to
small peptides and amino acids.
When metabolic acidosis is induced in rats by feeding
them ammonium chloride, they lose weight, and mus-
cle protein degradation is accelerated [27]. In studies
of isolated epitrochlearis muscles taken from these rats,
the ATP-dependent pathway is shown to have been ac-
tivated. Moreover, the activity of the pathway correlates
with the degree of acidosis, with the highest activity seen
with the most severe metabolic acidosis. When the mus-
cle is depleted of ATP, the increase in muscle protein
degradation is blocked. Inhibition of other pathways un-
der conditions of metabolic acidosis have little or no ef-
fect on protein degradation. There is also an increase in
gene expression, with higher levels of messenger ribonu-
cleic acids (mRNAs) encoding for various components of
the ubiquitin-proteasome pathway. Price and colleagues
[28] extended the in vivo studies of May et al [25] by
showing a corresponding increase in gene transcription,
as measured by increased levels of mRNAs for ubiquitin
and subunits of the proteasome from muscles of acidotic
adrenalectomized rats supplemented with physiological
doses of glucocorticoids. In the absence of acidosis or glu-
cocorticoids, or both, no increase in the levels of mRNAs
was seen. Similar results have been reported in chronic re-
nal failure rats with spontaneous metabolic acidosis [29].
Interestingly, when the spontaneous metabolic acidosis
of chronic renal failure was corrected with sodium bicar-
bonate, there was a corresponding normalization in rates
of protein degradation as well as levels of mRNAs.
Further insight into how glucocorticoids augment tran-
scription of genes for the ubiquitin-proteasome pathway
comes from cell culture work [30]. Glucocorticoids ap-
pear to stimulate subunit expression (C3) of the protea-
some by antagonizing the interaction of a specific protein,
NF-kappaB, with an NF-kappaB response element that
is on the promoter region for the subunit gene (C3).
NF-kappaB appears to act as a suppressor, inhibiting
transcription of the gene, and this suppressor action is
opposed by glucocorticoids.
Besides an increase in protein degradation, metabolic
acidosis is accompanied by an acceleration of amino acid
oxidation. Because they play an important role in pro-
tein metabolism, the branched-chain amino acids have
served as markers of malnutrition in various disease
states, including chronic kidney disease. The branched-
chain amino acids include valine, leucine, and isoleucine
and constitute 18% of the amino acids in muscle. Altered
cellular and serum levels of the branched-chain amino
acids are regularly found in patients with chronic kid-
ney disease [31], and the relative abundance reflects dis-
ease severity. As a result, there has been a good deal of
interest in elucidating the degradative pathways involv-
ing branched-chain amino acids. Degradation of these
amino acids can occur through various enzymes; how-
ever, the branched-chain alpha-keto acid dehydrogenase
(BCKAD) enzyme is the rate-limiting enzyme and ap-
pears to be the most important. BCKAD consists of 3
subunits: E1, which serves as a regulatory subunit; E2,
which serves as the site of decarboxylation; and E3, the
active enzyme.
Under normal conditions, BCKAD is largely phos-
phorylated and inactive. Under conditions of metabolic
acidosis, there is an increase in the activity of BCKAD
with an even greater increase in the maximal activity
(Vmax) of the enzyme [32]. Measurement of precursors
including mRNAs for E1a and E2 subunits of the en-
zyme seemed to suggest that there is an increased abun-
dance of the enzyme [33]; however, protein abundance
of the BCKAD enzyme as measured by Western blot-
ting techniques is unchanged. These results suggest that
Bailey: Metabolic acidosis in chronic kidney disease S-19
in a setting of metabolic acidosis, a greater fraction of
the BCKAD enzyme is present in the activated, dephos-
phorylated form. Moreover, an increase in production of
the enzyme is offset by an increase in its degradation,
paralleling the accelerated protein degradation that is al-
ready known to occur within the cell. Additional studies
by Price and colleagues [34] have shown that there are
both pH and glucocorticoid responsive elements within
the BCKAD genome that result in enhanced expression
of genes encoding BCKAD subunits. These responsive
elements have been localized to both the E1a and E2 sub-
units of the enzyme. Wang and colleagues further showed
that acidosis and glucocorticoids had differential effects
on the activation state of the enzyme [35]. They measured
the maximal BCKAD flux and the activation state, the ra-
tio of basal to total flux, in 2 cell types. One cell type did
not express the glucocorticoid receptor, while the other
cell type was transfected with genetic material to express
the glucocorticoid receptor. Acidification increased the
activation state from 67% to 83%, the maximal BCKAD
flux by 50%, and the BCKAD subunit content in both cell
types. In cells expressing the glucocorticoid receptor, dex-
amethasone increased the BCKAD activation state from
67% to 82%, while acidification increased the activation
state to 98%. Thus, it can be concluded that BCKAD ac-
tivity is influenced by both acidosis and glucocorticoids.
Similar results for BCKAD have been found in rat
studies. England and colleagues [36] studied BCKAD
activity in muscles of adrenalectomized rats in which
metabolic acidosis was induced in the presence or absence
of physiological doses of glucocorticoids. Only in aci-
dotic adrenalectomized rats receiving physiological doses
of glucocorticoids could an increase in BCKAD activity
in muscle be seen. Neither glucocorticoids nor acidosis
alone could increase BCKAD activity in muscle. Besides
in muscle, significant BCKAD activity has also been
reported in the liver. As a result, Price and colleagues
measured BCKAD activity in the liver [37] and found
surprising differences in BCKAD activity. In muscle of
acidotic adrenalectomized rats receiving dexamethasone,
basal and total BCKAD activity increased more than
2-fold. In contrast, basal BCKAD activity in liver of
rats with acidosis receiving glucocorticoids was 3-fold
lower. The authors concluded that reciprocal, tissue-
specific changes in BCKAD function occur in response to
acidosis.
CLINICAL STUDIES AND METABOLIC
ACIDOSIS
Clinical studies appear to parallel results drawn from
rat studies. Bergstrom found that essential amino acid
levels, including branched-chain amino acids, are subnor-
mal in patients with chronic kidney disease complicated
by metabolic acidosis [38]. Valine levels were noted to be
particularly reduced. This is important because low levels
of the essential amino acids, particularly valine, have been
linked to malnutrition. Bergstrom and colleagues [39]
also studied chronic kidney disease patients with vary-
ing degrees of metabolic acidosis and found that levels
of branched-chain amino acids appeared to decrease in
proportion to the severity of the acidosis.
The rat studies suggest that this decrease in the levels
of branched-chain amino acids is a direct result of ac-
celeration of amino acid oxidation through an increase
in BCKAD activity. Moreover, Mochizuki [40] reported
that low levels of branched-chain amino acids in patients
with chronic kidney disease could be corrected with the
addition of sodium bicarbonate to the diet. These studies
suggest that metabolic acidosis in chronic kidney disease
stimulates maladaptive responses in protein metabolism,
whereby protein degradation and essential amino acid
oxidation are stimulated, resulting in negative nitrogen
balance.
There have been a number of short- and long-term clin-
ical studies demonstrating that metabolic acidosis results
in negative nitrogen balance. Some of these studies have
used the leucine turnover technique in which C14-labeled
leucine is infused into a subject and the rate of appearance
of C14O2 is measured in the expired air. As an essential
amino acid, leucine can be incorporated into new protein
or catabolized to its corresponding branched-chain keto
acid with release of CO2 into the expired air: it cannot
by synthesized. Reaich and colleagues [41] administered
ammonium chloride to healthy volunteers to produce a
chronic metabolic acidosis.
The subjects lost weight and were in negative nitrogen
balance. Use of the leucine turnover technique confirmed
that there was an increase in both protein degradation
and amino acid oxidation. To account for possible differ-
ences in dietary intake, the human volunteers received
the same amount of calories and nutrients.
Correction of acidosis in humans with chronic kid-
ney disease has a favorable outcome on nitrogen bal-
ance. Reaich and colleagues [42] selected 9 volunteers
with chronic kidney disease not yet on dialysis and stud-
ied individual amino acid oxidation and protein degra-
dation rates with and without correction of acidosis. In
the first 4-week period, subjects were prescribed sodium
bicarbonate to correct the acidosis and then prescribed
sodium chloride for the following 4-week period. Sub-
jects were studied using the leucine turnover technique
before administration of the sodium bicarbonate, fol-
lowing administration of sodium bicarbonate, and then
following administration of the sodium chloride. Serum
bicarbonates were 15 ± 1 mMolar for the subjects at the
beginning of the study, 21 ± 1 mMolar following bi-
carbonate administration and 14 ± 1 mMolar following
sodium chloride administration. Leucine oxidation fell
from 13 ± 1.2 umol/kg/hr at the beginning of the study
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to 9.2 ± 0.9 umol/kg/hr following bicarbonate adminis-
tration and rose to 15 ± 1.9 umol/kg/hr following sodium
chloride adminstration. Similar trends were found when
protein degradation rates were studied. The amount of
leucine derived from protein degradation at the begin-
ning of the study was 122.4 ± 6.1, declined to 88.3 ± 6.9
following bicarbonate administration, and rose to 116.2 ±
9.1 following sodium chloride administration. This study
underscores how even short-term correction of metabolic
acidosis has implications for patients with chronic kid-
ney disease. Even patients with fairly advanced chronic
kidney disease can potentially benefit from correction of
metabolic acidosis.
Papadoyannakis and colleagues [43] conducted very
careful nitrogen balance studies in 6 patients with mean
creatinine clearance of 9.5 ± 2.6 mL/min/1.73 m2 (range
3.4–18.8 mL/min/1.73 m2) who were treated with alter-
nate courses of the same amount (0.7–1.2 mEq/kg/day)
of sodium chloride and sodium bicarbonate for a 10-day
period. Dietary intake was controlled for protein, calories
and potassium. When sodium chloride was administered
during the control period, one third of the subjects were
in negative nitrogen balance. They also were found to be
in positive sodium balance. Following administration of
sodium bicarbonate, plasma bicarbonate increased from
15.8 ± 0.7 mEq/L to 23.4 ± 1.2 mEq/L, and blood urea
nitrogen levels decreased significantly by 36%. Nitro-
gen balance improved for all subjects, and all subjects
were in positive nitrogen balance. During the period that
the subjects were receiving sodium bicarbonate, they
were in neutral sodium balance. For patients with ten-
uous renal function, careful attention to protein intake
and acid base balance can result in their maintaining pos-
itive protein balance and avoiding protein malnutrition.
In dialysis patients, there have been a number of stud-
ies to show that correction of metabolic acidosis has im-
portant ramifications on nutritional status. Graham and
colleagues [44] studied 6 chronic hemodialysis patients
before and after correction of acidosis. The study con-
sisted of two 4-week periods separated by a 2-week
washout period. During one period, the subjects were
prescribed a final dialysate concentration of 35 mMol/L
bicarbonate. During the other period, 40 mMol/L bicar-
bonate was prescribed for the dialysate. As the target
predialysis bicarbonate was greater than 23 mMol/L in
the latter group, subjects were given oral sodium bicar-
bonate if the target was not achieved. Food diaries were
also recorded. During the washout period, subjects were
assigned to the standard 35 mMol/L bicarbonate dialysate
bath. The leucine turnover technique was utilized to mea-
sure rates of protein degradation and amino acid oxida-
tion, and the studies were performed on nondialysis days
to avoid the confounding variables associated with the
dialysis procedure. Serum bicarbonate levels were 18.5 ±
0.7 mMol/L for the standard 35 mMol/L bicarbonate
dialysate and 24.8 ± 0.7 for the 40 mMol/L bicarbonate
dialysate. With correction of the acidosis, subjects demon-
strated lower rates of both protein synthesis (122.0 ± 6.8
umol/kg/hr vs 172.3 ± 7.6 umol/kg/hr) and protein degra-
dation (130.6 ± 7.2 umol/kg/hr vs 180.8 ± 7.3 umol/kg/hr),
which was statistically significant from the control period.
The authors were not able to demonstrate differences in
amino acid oxidation, serum albumin levels, or in anthro-
pometric measurements (attributed to the short period of
the study). Similar results were seen in 7 CAPD patients
studied by Graham and colleagues [45]. All subjects had
a mean serum bicarbonate of less than 22 mM/L for at
least 3 months prior to the study. The study consisted
of 2 consecutive 4-week periods separated by a 2-week
washout period. During one period, subjects underwent
their normal CAPD regimen. During the other period,
subjects were given sufficient oral bicarbonate to correct
their serum bicarbonate to 25 mM/L. During each 4-week
period, subjects were studied using the leucine turnover
technique. The serum bicarbonate rose from 19.3 ± 0.5
mMol/L during the standard dialysis period to 26.2 ±
0.9 during the bicarbonate supplement period. With cor-
rection of the metabolic acidosis, both protein synthesis
(PS) rate and protein degradation (PD) rate declined (PS:
acid 211.7 ± 9.8, bicarbonate 142.3 ± 4.2 umol/kg/hr; PD:
acid 200.6 ± 8.5, bicarbonate 132.4 ± 3.7 umol/kg/hr).
Although Graham and colleagues did not find changes
in leucine oxidation, serum albumin levels, or in anthro-
pometric measurements, they did note a statistically sig-
nificant decline in 3-methylhistidine levels. The latter is
considered a valid marker for skeletal muscle breakdown
in humans, and its normalization during the short term of
the study suggested that it could have favorable long-term
outcomes on nutritional status. These results provided
further confirmation that metabolic acidosis is a catabolic
stimulus and that correction of the acidosis has a positive
influence on decreasing muscle protein breakdown.
Although short-term correction of metabolic acidosis
in normal and uremic subjects showed a decrease in pro-
tein degradation, the long-term effects of better correc-
tion of acidosis on nutritional status in end-stage renal
disease patients remained unknown until Stein and col-
leagues [46] looked at 200 newly initiated CAPD patients
randomized to a high (lactate of 40 mMol/L) or low (lac-
tate 35 mMol/L) alkali dialysate for 1 year. Additional
alkali in the form of calcium carbonate and sodium bi-
carbonate was also used to correct acidosis in the high-
alkali dialysate group. Serum bicarbonate and arterial pH
were 7.44 ± 0.004 and 27.2 ± 0.3 mMol/L, respectively, in
the high-alkali dialysate group and 7.40 ± 0.004 and 23.0
± 0.3 mMol/L, respectively, in the low-alkali dialysate
group. There were no differences in dialysis dose be-
tween the 2 groups. After 1 year, there was a significantly
higher increase in body weight in the high-alkali group
(6.1 ± 0.66 kg) vs (3.71 ± 0.56 kg) in the low-alkali group.
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Midarm circumference was higher in the high-alkali
group (1.26 ± 0.16 cm) than in the low-alkali group (0.61
± 0.16 cm). There were no statistical differences noted in
tricep fold thickness or serum albumin levels. The higher-
alkali group had fewer hospitalizations/patient/year
(1.13 ± 0.16 vs 1.71 ± 0.22 year, respectively) and spent
fewer days/year in the hospital (16.4 ± 1.4 vs 21.2 ± 1.9,
respectively) than did the lower-alkali group. The authors
attributed the improvement in morbidity in terms of num-
ber of hospitalizations and days in the hospital per year
to an improvement in nutritional state. They noted that
increases in alkali were associated with weight gain and
improved indices of muscle mass, indicating that patients
were in positive nitrogen balance.
Confirmation that the ubiquitin-proteasome system is
active in muscles of patients with chronic kidney disease
comes from a study of 8 CAPD patients by Pickering
and colleagues [47]. All patients agreed to have muscle
biopsies at the beginning of the study and again 4 weeks
later, following addition of alkali in the form of calcium
carbonate or sodium bicarbonate to the diet. Serum bicar-
bonate values increased in all patients as did weight, body
mass index, and plasma branched-chain amino acid levels.
Muscle levels of ubiquitin RNA decreased significantly.
The authors concluded that even a small correction in
the serum bicarbonate level improved nutritional status.
Their study also provided evidence for down-regulation
of branched-chain amino acids and muscle proteolysis via
the ubiquitin-proteasome system.
Metabolic acidosis may also have detrimental effects
on protein synthesis. Using ammonium chloride, Ballmer
and colleagues [48] induced metabolic acidosis in 8
healthy volunteers on a constant metabolic diet before
and during 2 different degrees of metabolic acidosis. Al-
bumin synthesis rates were measured by intravenous in-
jection of radiolabeled phenylalanine after an overnight
fast. With low-dose ammonium chloride (2.1 mMol/kg
body weight), serum pH and bicarbonate fell from pH
7.431 ± 0.013 and 24.5 ± 1.0 mMol/L to pH 7.375 ±
0.019 and 19.1 ± 2.1 mMol/L; with high-dose ammonium
chloride (4.2 mMol/kg body weight), serum pH and bi-
carbonate fell from pH 7.436 ± 0.014 and 25.0 ± 1.2
mMol/L to pH 7.309 ± 0.053 and 15.1 ± 1.6 mMol/L.
Researchers found that the fractional synthesis rate of al-
bumin decreased from 9.9 ± 1.0% per day in the control
group to 8.4 ± 0.7% in the low-dose acid group. Because
this decrease was not significant, they then administered
the higher dose of ammonium chloride and found that
the fractional synthesis rates declined significantly from
8.3 ± 1.3% per day in the control group to 6.3 ± 1.1%
in the high-dose acid group. They also noted a significant
decline in serum albumin levels.
Ballmer and colleagues’ work has been difficult to du-
plicate in clinical studies. Brady and Hasbargen [49] stud-
ied 36 chronic, stable hemodialysis patients who had a
mean serum bicarbonate of ≤18 mEq/L on predialysis
laboratory values during the preceding 3 months. Sub-
jects were randomized to a standard bicarbonate bath of
35 mEq/L or to a serum bicarbonate bath of 40 mEq/L.
The latter subjects received additional oral bicarbonate
following 2 weeks of therapy if their predialysis serum
bicarbonate concentration was <22 mEq/L. The study
lasted 16 weeks, and 32 subjects completed the study. Al-
though the serum bicarbonate concentrations were sig-
nificantly different between the 2 groups at the end of
the study (control bicarbonate 17.3 ± 3.2 mEq/L vs ex-
perimental bicarbonate 20.2 ± 2.9 mEq/L), the serum
albumin concentrations were not statistically different.
In contrast, Movilli and colleagues [50] studied 12
chronic, stable hemodialysis patients who were evalu-
ated before and after correction of serum bicarbonate.
Serum bicarbonate levels and arterial pH increased, re-
spectively, from 19.3 ± 0.6 mMol/L to 24.4 ± 1.2 mMol/L
(P value <0.0001) and 7.34 ± 0.03 to 7.40 ± 0.02 (P value
<0.0001) while the serum albumin increased from 34.9 ±
2.1 g/L to 37.9 ± 2.9 g/L (P value <0.01). The authors also
noted that the normalized protein catabolic rate (nPCR)
decreased significantly. Differences in design could have
altered the results. Although Brady and Hasbargen [49]
used a randomized control study and a far larger cohort,
the experimental group did not achieve a normal serum
bicarbonate. Moreover, there was a larger variation in
the serum bicarbonate concentrations, which may have
made it difficult to elicit subtle differences in serum albu-
min levels. Movilli and colleagues’ [50] work does illus-
trate that the nPCR is elevated in the setting of metabolic
acidosis. The authors noted that the clinician could misin-
terpret this elevation in the nPCR and erroneously con-
clude that a dialysis patient was doing well, when actually,
the elevated nPCR reflected an increase in catabolism of
endogenous protein stores. Bastani and colleagues [51]
retrospectively examined the relationship between the
serum bicarbonate and the nPCR in 70 chronic hemodial-
ysis patients over a 4- to 6-month period. They found an
independent and inverse association between the serum
bicarbonate and the nPCR, and noted that the slope of the
regression increased abruptly below a serum bicarbonate
of 15 mEq/L. They concluded that the nPCR appeared to
be greatly exaggerated at moderate to severe reductions
in the serum bicarbonate, reinforcing the view that the
nPCR should be interpreted with caution in the setting
of metabolic acidosis.
In summary, there is a wealth of data to show that
metabolic acidosis has deleterious effects, particularly
in patients with chronic kidney disease. A variety of
hormonal abnormalities can occur, including insulin
resistance, suppression of the growth hormone/IGF-1
axis, and increased circulating levels of glucocorticoids.
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Vitamin D production is suppressed and parathyroid hor-
mone’s sensitivity to calcium is reduced. In the absence
of appropriate therapy, skeletal growth is impaired, mus-
cle protein is subject to increased catabolism, and amino
acids undergo increased oxidation: negative nitrogen bal-
ance results, and muscle wasting occurs. Ultimately, ap-
propriate correction of metabolic acidosis with alkali can
do much to ameliorate and correct this condition.
Reprint requests to James L. Bailey, Room 338 Woodruff Memorial
Research Building, 1639 Pierce Drive, Emory University, Atlanta, GA
30322.
E-mail: james.l.bailey@emory.edu
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